Reach Us +1-218-451-2974


Shifu Xiao | OMICS International
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Shifu Xiao

Professor and Director, Department of Geriatric Psychiatry


 Dr Xiao is Professor and Director of the Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine; Director of Alzheimer Disease and Related Disorders Center, Shanghai Jiaotong University. His Academic positions include: Vice Chair of Chinese Geriatrician Association, Vice Chair of Alzheimer Disease China, Vice Chair of Psychological Evaluation Committee of Chinese Mental health Society, and Member of Cognition and Dementia Committee of Chinese Neurology Association. Advisor of the State Food and Drug Administration and Consultant of the Medical Science and Technology Center, China Ministry of Health.


Research Interest

Dr Xiao’s research interest mainly focus on diagnosis and treatment of dementia and depression in the elderly. He is PI of the CLAS study granted by China Ministry of Science and Technology. He has conducted more than 10 phase II/III multi-center, randomized, placebo-controlled, clinical trials for anti-Alzheimer medications approved by SFDA in the last decade. He has more than 100 original articles as first author or co-author and 36 scientific books as editor or contributor published.